EPCAM and non-small cell lung carcinoma: Compared with the use of IMNs alone, the capture rate could reach 90% with the combination of anti-EpCAM-MNs and anti-FRα-MNs, which is about 10–50% higher than anti-EpCAM-MNs alone (P < 0.01) in mimics of NSCLC clinical samples.